Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.39% and ...

Eli Lilly (LLY) has filed a lawsuit against the heads of the Department of Health and Human Services and one of its agencies, seeking a court ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Nevertheless, the company's lead obesity candidate ... Adam Spatacco has positions in Eli Lilly. The Motley Fool has no ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

Conditions are getting a bit more challenging for the drugmaker.

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly (LLY) has been one of the most searched ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to ...